Early experience with the automatic implantable cardioverter defibrillator in sudden death survivors.
Medical management of life-threatening ventricular arrhythmias is difficult because of the toxicity and limited efficacy of antiarrhythmic drugs. The automatic implantable cardioverter defibrillator (AICD) offers protection against malignant ventricular arrhythmias and allows some patients to be managed without antiarrhythmic drugs. We reviewed our experience with the AICD to determine its safety and efficacy. Since June 1987, 24 patients (mean age 63 years) who survived out-of-hospital ventricular fibrillation or hemodynamically unstable ventricular tachycardia not associated with acute myocardial infarction had implantation of an AICD. None had inducible monomorphic ventricular tachycardia associated with ventricular aneurysm. Twenty-three had abnormal left ventricular function (mean ejection fraction 0.32). There were no operative deaths and three complications. At last follow-up (mean 8.9 months) 23 patients were alive. Eight patients had one or more AICD discharges associated with symptomatic or monitored cardiac arrest. AICD implantation can be performed with low risk and appears to be an effective alternative to antiarrhythmic therapy with toxic drugs.
Paull
D L
DL
Section of Cardiothoracic Surgery, Virginia Mason Clinic, Seattle, Washington 98111.
Fellows
C L
CL
Guyton
S W
SW
Anderson
R P
RP
D000328:Adult; D000368:Aged; D003645:Death, Sudden / Q000517:prevention & control*; D004554:Electric Countershock / Q000295:instrumentation*; D005260:Female; D005500:Follow-Up Studies; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged; D019736:Prostheses and Implants; D013610:Tachycardia / Q000628:therapy; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000628:therapy